Capcom’s Monster Hunter Bridge to be Exhibited in the Osaka Healthcare Pavilion at Expo 2025, Osaka, Kansai, Japan!
Capcom Co., Ltd. (TOKYO:9697) today announced that the company will sponsor the Osaka Healthcare Pavilion, which is being exhibited by the Expo 2025, Osaka Pavilion Promotion Committee at Expo 2025, Osaka, Kansai, Japan (Expo 2025, below). Further, the company announced that it will exhibit an interactive experience dubbed Monster Hunter Bridge at the Pavilion in the XD Hall, where visitors can experience the future of entertainment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829488620/en/
Monster Hunter Bridge key art (Graphic: Business Wire)
The theme of the upcoming Expo 2025 is “Designing Future Society for Our Lives.” Inspired by the “REBORN” theme of the Osaka Healthcare Pavilion, Capcom decided to exhibit an interactive attraction that incorporates the concept of nature, living things, and the wonder of life, which are important themes in the Monster Hunter series.
Exhibit Details
Monster Hunter Bridge is a wholly-unique attraction that Capcom created exclusively for Expo 2025. Visitors to the hall will don specialized AR devices and be able to enjoy this interactive attraction that weaves together a 360-degree theater, immersive audio, and vibrating floor. Capcom is developing Monster Hunter Bridge with the aim of blending dreams with reality to provide an immersive experience like never before. The company hopes that visitors look forward to this one-of-a-kind Monster Hunter attraction that will bring them up close with Felyne as well as incredible monster encounters, and can only be experienced at Expo 2025.
Facilities Details
The attraction will be housed in a cylinder-shaped theater within the XD Hall that will measure approximately 12 meters in diameter and 5 meters in height and will be created as part of the Osaka Healthcare Pavilion. Capcom will exhibit Monster Hunter Bridge there by creating a space inside the XD Hall that projects the world of Monster Hunter in 360 degrees, utilizing transparent LED displays on the internal walls and ceiling and projectors on the floor. The company developed new specialized AR devices for visitors that feature 105 degrees of visibility in order to create Expo 2025’s most engaging experience. In addition, the company will enhance the immersion of the space by outfitting it with a multitude of speakers set behind the transparent LED displays, wrapping visitors in 360 degrees of sound while vibrations from the floor are synchronized with the on-screen action.
The company is creating these facilities with the cooperation of partner companies exclusively for Monster Hunter Bridge.
Promotional Ticket Campaign
With the desire to contribute to the development and promotion of Expo 2025, which is being held where Capcom was founded, the company will carry out an Expo 2025 “super-advanced one-day pass” double ticket promotional campaign in which it will give away a total of 80,890 tickets to Expo 2025. The promotion is available to everyone who registers for Capcom ID, a unified account with which users can conveniently manage various Capcom games and web services. The company encourages people to refer to the promotional ticket campaign website for more details.
*Only residents of Japan are eligible to participate in the round one entry period. Please refer to the promotional ticket campaign website regarding eligibility for future campaign entry periods.
Capcom is currently developing Monster Hunter Bridge with the aim of providing a special entertainment experience where dreams and reality become one. The company hopes to create the absolute best content at the event and bring success to the Expo 2025, Osaka Pavilion Promotion Committee.
ABOUT the Monster Hunter series:
The Monster Hunter series consists of hunting action games that pit players against giant monsters in beautiful natural environments. After the series created a social phenomenon through play on handheld consoles and solidified its standing as one of Japan’s most beloved game series, it went on to global-brand status with the release of Monster Hunter: World in 2018. With cumulative sales of the series now exceeding 100 million units, Monster Hunter has grown into a global phenomenon.
[Exhibit Details]
1. Name | Monster Hunter Bridge |
2. Location | XD Hall, Osaka Healthcare Pavilion, Expo 2025, Osaka, Kansai |
3. Term | April 13, 2025 - October 13, 2025 |
4. Admission | Free* |
5. Official Website | |
6. Ticket Promotion Website | |
*Entry to this attraction will be by reservation only. Details will be provided at a later date. | |
*A separate ticket must be purchased to enter Expo 2025, Osaka, Kansai. | |
ABOUT CAPCOM
Capcom is a leading worldwide developer, publisher and distributor of interactive entertainment for game consoles, PCs, handheld and wireless devices. Founded in 1983, the company has created hundreds of games, including groundbreaking franchises Resident Evil™, Monster Hunter™, Street Fighter™, Mega Man™, Devil May Cry™ and Ace Attorney™. Capcom maintains operations in the U.S., U.K., Germany, France, Hong Kong, Taiwan, Singapore and Tokyo, with corporate headquarters located in Osaka, Japan. More information about Capcom can be found at https://www.capcom.co.jp/ir/english/
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829488620/en/
Contacts
Capcom Public Relations & Investor Relations Section
Daniel Levine
+81-6-6920-3623
daniel-levine@capcom.com
Yoshiko Ikeda
+81-6-6920-3623
yoshiko-ikeda@capcom.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom